凌雲光(688400.SH):參股公司長光辰芯向香港聯交所遞交上市申請
格隆匯6月20日丨凌雲光(688400.SH)公佈,公司從參股公司長春長光辰芯微電子股份有限公司(以下簡稱“長光辰芯”)處獲悉,其已於2025年6月19日向香港聯合交易所有限公司(以下簡稱“香港聯交所”)遞交了首次公開發行境外上市股份(H股)並在香港聯交所主板上市(以下簡稱“本次發行”)的申請,並於同日在香港聯交所網站刊登了本次發行的申請資料。
長光辰芯主營業務爲高性能CMOS圖像傳感器的研發、設計、測試與銷售以及相關的定製業務,其產品主要應用於機器視覺、科學儀器和專業影像等高科技領域。截至本公告披露日,公司持有長光辰芯10.22%的股份。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.